How AI is revolutionising drug development

17 June 2024 - In high-tech labs, workers are generating data to train AI algorithms to design better medicine, faster. But ...

Read more →

The threat of fungal infections is growing. Why is it so hard to make new drugs?

11 February 2024 - Last summer, the FDA denied an application for a new anti-fungal drug called olorofim, sending it back ...

Read more →

FDA and EMA launch parallel scientific advice pilot program for complex generics

7 February 2024 - CDER’s Office of Generic Drugs and the EMA launched a voluntary pilot program to facilitate concurrent discussions ...

Read more →

Addressing the challenge of common chronic diseases — a view from the FDA

3 February 2024 - Of the 10 most common causes of death in the United States, 7 are chronic diseases: ...

Read more →

MedChem a game changer in identifying lifesaving new drugs

8 November 2023 - The Australian Government is ensuring the next generation of lifesaving drugs and world-class medical treatments can be ...

Read more →

Germany, Belgium and France among those hit hardest as Commission’s Pharma-legislation proposals risk Europe losing a third of its share of global R&D by 2040

6 November 2023 - The European Federation of Pharmaceutical Industries and Associations (EFPIA) is publishing new research which assesses the ...

Read more →

NICE launches refreshed support service for life sciences industry

6 November 2023 - NICE has today launched its refreshed support service for the life sciences sector, NICE Advice.  ...

Read more →

FDA launches pilot program to help further accelerate development of rare disease therapies

29 September 2023 - Today, the US FDA is taking steps to help further accelerate the development of novel drug and ...

Read more →

UKHSA unveils VDEC in ‘step change’ for UK’s growing vaccine capabilities

7 August 2023 - Vaccine Development and Evaluation Centre to be at forefront of UK’s ability to research and develop vaccines ...

Read more →

How a drug maker profited by slow walking a promising HIV therapy

22 July 2023 - Gilead delayed a new version of a drug, allowing it to extend the patent life of a ...

Read more →

A priority review voucher program to fuel generic drug development

6 July 2023 - Millions of Americans report that they are unable to fill their prescriptions or are not taking their ...

Read more →

FDA announces additional steps to modernise clinical trials

6 June 2023 - Agency requesting feedback on the draft recommendations and how they should be applied to increasingly diverse trial ...

Read more →

New features further strengthen Priority Medicines scheme (PRIME)

4 April 2023 - The EMA is introducing a number of new features to the PRIority Medicines (PRIME) scheme to ...

Read more →

Drug repurposing during the COVID-19 pandemic: lessons for expediting drug development and access

20 March 2023 - The COVID-19 pandemic created a large, sudden unmet public health need for rapid access to safe and ...

Read more →

Medicare will take R&D costs, effectiveness into account when it negotiates drug prices. But studies show that doesn’t affect prices.

10 March 2023 - By law, Medicare will have to take a medication’s efficacy and its research and development costs ...

Read more →